bluebird bio Inc (NASDAQ:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, announced that Philip Gregory, D. Phil., is joining the company as its Chief Scientific Officer and a member of the leadership team.

Dr. Gregory comes to bluebird bio from Sangamo BioSciences Inc., where he most recently served as Chief Scientific Officer and Senior Vice President, Research. At Sangamo, Dr. Gregory was responsible for setting the scientific direction of the company, prosecuting the development of the company’s genome editing platform and overseeing the early discovery and development of IND candidates.

“Philip brings a wealth of pioneering leadership and expertise in the field of genome editing and gene therapy to bluebird bio during an exciting point in our company’s growth,” said Nick Leschly, chief bluebird. “Philip shares our unwavering commitment to deliver therapies that have the potential to transform the lives of patients. The breadth and depth of his knowledge and experience will be crucial as we build a leading gene therapy products company.”

“bluebird bio is uniquely positioned with deep expertise and a broad platform across lentiviral vectors and genome editing, with numerous promising therapeutic applications,” said Dr. Gregory. “I am excited to be part of the team that is building and expanding upon this foundational work to bring potentially transformative therapies to patients.”

Dr. Gregory holds a D.Phil. in Biochemistry from Oxford University, and B.Sc. in Microbiology from Sheffield University. (Original Source)

Shares of bluebird bio Inc closed last Friday at $180.81 . BLUE has a 1-year high of $197.35 and a 1-year low of $25.25. The stock’s 50-day moving average is $166.67 and its 200-day moving average is $116.99.

On the ratings front, bluebird bio Inc has been the subject of a number of recent research reports. In a report issued on June 10, BMO analyst Jim Birchenough reiterated a Buy rating on BLUE, with a price target of $200, which represents a potential upside of 10.6% from where the stock is currently trading. Separately, on the same day, Roth Capital’s Debjit Chattopadhyay maintained a Buy rating on the stock and has a price target of $192.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Jim Birchenough and Debjit Chattopadhyay have a total average return of 39.4% and 32.2% respectively. Birchenough has a success rate of 62.7% and is ranked #21 out of 3624 analysts, while Chattopadhyay has a success rate of 69.5% and is ranked #16.

In total, 7 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $206.40 which is 14.2% above where the stock closed last Friday.

bluebird bio Inc is a clinical-stage biotechnology company. It is engaged in developing potentially transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy.